EcoDrugPlus

Melanoma Receptor Tyrosine-Protein Kinase-Like

Ensembl ID : ENSAPOG00000005941
Gene Symbol: LOC110970701
2 Cross references
212 Possible Orthologues:

Melatonin Receptor 1a

Ensembl ID : ENSAPOG00000011257
Gene Symbol: MTNR1A
3 Cross references
190 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSAPOG00000022263
Gene Symbol: MME
4 Cross references
234 Possible Orthologues:

Membrane Primary Amine Oxidase-Like

Ensembl ID : ENSAPOG00000011676
Gene Symbol: LOC110947054
2 Cross references
402 Possible Orthologues:

Metabotropic Glutamate Receptor 2-Like

Ensembl ID : ENSAPOG00000016803
Gene Symbol: LOC110947938
3 Cross references
210 Possible Orthologues:

Metabotropic Glutamate Receptor 3-Like

Ensembl ID : ENSAPOG00000013258
Gene Symbol: LOC110949751
3 Cross references
212 Possible Orthologues:

Metabotropic Glutamate Receptor 5-Like

Ensembl ID : ENSAPOG00000003294
Gene Symbol: LOC110961815
3 Cross references
212 Possible Orthologues:

Methionine Aminopeptidase 2-Like

Ensembl ID : ENSAPOG00000012858
Gene Symbol: LOC110967444
4 Cross references
229 Possible Orthologues:

Microtubule-Associated Protein Tau-Like

Ensembl ID : ENSAPOG00000021397
Gene Symbol: LOC110961309
2 Cross references
205 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSAPOG00000012189
Gene Symbol: MAPK1
4 Cross references
208 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSAPOG00000012459
Gene Symbol: MAPK1
3 Cross references
210 Possible Orthologues:

Mitogen-Activated Protein Kinase 1-Like

Ensembl ID : ENSAPOG00000013475
Gene Symbol: LOC110945879
2 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).